AMERICAN SOCIETY OF CLINICAL ONCOLOGY

FDA accepted Elevar Therapeutics' NDA resubmission for rivoceranib plus camrelizumab as a frontline treatment for uHCC, with a PDUFA date of March 20, 2025. The phase 3 CARES-310 study showed a median OS of 23.8 months with the combination vs 15.2 months with sorafenib, and a median PFS of 5.6 months vs 3.7 months, respectively.

ASCO analysis finds 70% of U.S. counties lack active cancer treatment trials, and 25% of adults over 55 must travel >2 hours for access. 90% of adult patients don't participate in trials, and only half have local access. Geographic and workforce disparities in oncology care are highlighted, with calls for bringing trials to patients and increasing workforce diversity.

FDA accepts Elevar Therapeutics' NDA resubmission for rivoceranib + camrelizumab as first-line treatment for uHCC, with a PDUFA target action date of March 20, 2025. The resubmission is supported by the final survival analysis of the CARES-310 study, which showed significant improvements in overall survival.

The FDA accepted the resubmission of an NDA for rivoceranib and camrelizumab as a first-line treatment for uHCC, with a PDUFA target action date of March 20, 2025. The combination, an oral VEGF TKI and a PD-1 inhibitor, showed a median overall survival of 23.8 months in the CARES-310 study, the longest in a global phase 3 trial for this patient population.

Research highlights measurable residual disease in acute myeloid leukemia (AML) before allogeneic transplant, emphasizing the importance of DNA sequencing and precision medicine. Studies also address racial and ethnic disparities in access to medical advancements, clinical trials, and allogeneic hematopoietic cell transplantation, with initiatives aiming to reduce barriers and improve outcomes for diverse populations.

Courtney Van Houzen, PharmD, discusses bringing bispecific antibody treatments to community settings, inspired by a patient's need for continuity of care. Promising efficacy and safety of fianlimab and cemiplimab in advanced melanoma is highlighted. Inavolisib plus palbociclib and fulvestrant gains FDA approval for HR+/HER2- PIK3CA-mutated breast cancer. Talazoparib plus enzalutamide shows survival improvement in mCRPC. The TWINPEAK trial initiates with PT886 and pembrolizumab for gastric and GEJ cancers.

A study revealed that pain management specialists were rarely consulted for cancer-related pain, with providers often prescribing narcotics. The review analyzed 15 physician group practices from 2016 to 2022, finding 38.6% of episodes and 55% of patients received narcotics. Prescription patterns varied widely among providers, with 7 drugs accounting for 87.5% of narcotic prescriptions. ASCO guidelines recommend opioids for moderate to severe cancer-related pain, starting at the lowest effective dose.

OncLive National Fellows Forum on Lung Cancer featured presentations by Amanda Herrmann, Chinmay Jani, and Cameron Oswalt. Herrmann discussed quantifying patient-level time costs in lung cancer clinical trials, Jani examined the impact of air quality on lung cancer mortality, and Oswalt focused on improving palliative care in NSCLC. Herrmann's TIME TOX Lung study found increased time toxicity in recent trials, Jani's research highlighted rising asbestos and air pollution-associated lung cancer mortality in populous countries, and Oswalt's analysis suggested early palliative care leads to better end-of-life outcomes.

NCCN guidelines prefer cabozantinib plus nivolumab and lenvatinib plus pembrolizumab for RCC treatment. The KEYNOTE-B61 trial showed a 50% ORR with pembrolizumab and lenvatinib in nccRCC patients, leading to FDA approval and NCCN preference. Cabozantinib plus nivolumab also showed a 54% ORR in a phase 2 trial, despite mixed histologies. Dosing strategies for TKIs like cabozantinib and lenvatinib emphasize de-escalation for better patient tolerance and outcomes. Lenvatinib plus everolimus is an alternative for patients unfit for immunotherapy.

Recruiting international students to US oncology fellowship programs is crucial due to the growing demand for well-trained oncologists. Program directors must address the unique challenges these fellows face, such as acclimatization and visa status, to ensure their success. International fellows bring grit, flexibility, and maturity, enriching the program's diversity and patient care. Programs should promote inclusivity and provide mentorship to support these fellows throughout their training and career.